Ribosomal protein L23a pseudogene 68 (RPL23AP68)

Ribosomal protein L23a pseudogene 68 (RPL23AP68) is classified as a pseudogene of the ribosomal protein L23a gene. Pseudogenes are genomic DNA sequences similar to normal genes but are typically non-functional; they generally do not encode functional proteins due to mutations, truncations, or the absence of regulatory features necessary for gene expression[3]. RPL23AP68 shares sequence homology with the canonical ribosomal protein L23a gene but, as a pseudogene, does not produce a protein product. Most pseudogenes, including RPL23AP68, do not have known biological functions, are not considered therapeutic targets, are not known to interact with drugs, and do not have direct disease or biomarker relevance[3]. RPL23AP68 is not a therapeutic target (receptor, enzyme, transporter, etc.), but rather a pseudogene[3]. If you are seeking information on the functional ribosomal protein, the relevant gene is RPL23A (ribosomal protein L23a), not RPL23AP68[1]. There is no evidence of RPL23AP68 being involved in disease, drug activity, or clinical biomarkers[3]. Other pseudogenes in the RPL23A family, such as RPL23AP53, have been experimentally studied for correlation with disease characteristics (e.g., prognosis or immune profile in melanoma)[2]. However, these findings are specific to other pseudogene family members and cannot be generalized to RPL23AP68 based on current data[3]. Ribosomal protein L23a (the protein-coding gene, not the pseudogene) is a component of the large ribosomal subunit involved in protein synthesis, but pseudogenes like RPL23AP68 lack this role[1]. In summary, RPL23AP68 is a non-coding pseudogene and not a functional protein or validated molecular target for therapeutic intervention[3].

Other names

RPL23AP68ribosomal protein L23a pseudogene 68